VivaVision Biotech Files Hong Kong IPO to Advance Ophthalmology Pipeline
CompanyDeals

VivaVision Biotech Files Hong Kong IPO to Advance Ophthalmology Pipeline

Astellas’ VENTANA CLDN18 Assay Wins NMPA Approval as First Companion Diagnostic for VYLOY
Medical Device

Astellas’ VENTANA CLDN18 Assay Wins NMPA Approval as First Companion Diagnostic for VYLOY

CompanyDeals

Genhouse Bio Partners with Gilead on $1.5 Billion Synthetic Lethal Cancer Project GH31

CompanyDrug

3SBio’s Amdokitug Wins NMPA Approval for Moderate-to-Severe Plaque Psoriasis

Bio-Thera’s Gotenfia Wins European Approval as Simponi Biosimilar
CompanyDrug

Bio-Thera’s Gotenfia Wins European Approval as Simponi Biosimilar

First Imaging Raises $14.5 Million to Advance AI-Powered Intraoperative Imaging
CompanyDeals

First Imaging Raises $14.5 Million to Advance AI-Powered Intraoperative Imaging

Company

CARsgen Therapeutics to Invest $54 Million in Shanghai CAR-T Manufacturing Facility

GSK Reports 7% Revenue Growth to $44.7 Billion in 2025; Oncology Surges 43%
Company

GSK Reports 7% Revenue Growth to $44.7 Billion in 2025; Oncology Surges 43%

CompanyMedical Device

Novocure’s Optune Pax Wins FDA Approval for Pancreatic Cancer; Zai Lab China Rights in Play

CompanyDeals

China Medical System Licenses Teikoku’s Lidoderm for Postherpetic Neuralgia in China

Organon Reports 2025 Revenue Decline to $6.2 Billion; JADA Sale and Portfolio Pressures Weigh
Company

Organon Reports 2025 Revenue Decline to $6.2 Billion; JADA Sale and Portfolio Pressures Weigh

Salubris Pharma Files Hong Kong IPO for Secondary Listing to Expand Cardiorenal Metabolic Franchise
CompanyDeals

Salubris Pharma Files Hong Kong IPO for Secondary Listing to Expand Cardiorenal Metabolic Franchise